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Among the several strategies explored for (1) the enhance-
ment of the immune response to influenza immunization,
(2) the improvement of the vaccine acceptability and (3) the
overcoming of the egg-dependency for vaccine production,
intradermal administration of influenza vaccine emerges as a
promising alternative to conventional intramuscular route,
thanks to the recent availability of new delivery devices and
the perception of advantages in terms of immunogenicity,
safety, reduction of antigen content and acceptability.
Data from clinical trials performed in children, adults
,60 y and elderly people and post-marketing surveillance
demonstrate that actually, licensed intradermal influenza
vaccines, Intanza
TM 9 and 15 mg and Fluzone
TM Intradermal,
administered by the microinjection system Soluvia
TM, show
an excellent acceptability, tolerability and safety profile.
Formulations containing 9 and 15 mg per strain demonstrate,
respectively, comparable and superior immunogenicity than
conventional intramuscular vaccines. Licensed intradermal
influenza vaccines can be considered a valid alternative to
standard intramuscular vaccination offering significant
advantages in low-responder populations and helping to
increase influenza vaccination coverage rates especially in
people with fear of needles or high apprehension associated
with annual vaccination.
Introduction
Annual vaccination represents the main public health strategy for
reducing outpatient visits, hospitalizations and deaths due to
influenza viruses, especially in at-risk populations such as children,
the elderly, pregnant women and people with chronic diseases.
1
Traditional targets of annual influenza vaccination are subjects
classified as being at high risk, but recent recommendations
broad vaccine administration to larger numbers of people: in the
USA Centers for Disease Control and Prevention recommended
seasonal influenza vaccination to all people aged $6mo for the
2010–11 season.
2
In Europe, the broadening of recommendation is object of
active discussion by scientific community and policy makers.
However, influenza vaccine and its production cycle present some
important limitations. First, clinical efficacy of conventional
influenza vaccines drops from 70–90% in young adults to 30–
70% in patients with underlying conditions and to 17–53% in
the elderly.
2,3 Furthermore, patients receiving immunosuppressive
regimens experience impaired response to influenza vaccine, due
to several mechanisms only partly known;
4,5 immune senescence,
with reduction of Langerhans cells, decreased activity of antigen
presenting cells, reduced expression of MHC class I and II
molecules, decreased production of mature naïve T cells by the
thymus, is the most important reason for the lack of efficacy of
influenza vaccine in the elderly.
6-8 Moreover, antigenic mismatch
between the vaccine and the circulating virus strains can nega-
tively impact on vaccine effectiveness, resulting in a decrease in
vaccine-induced immunogenicity and an inadequate protection of
vaccinees.
9-14
Second, a well-established barrier to influenza immunization is
a general lack of patient acceptance of traditional intramuscular
vaccination: results obtained from recent European surveys
indicate that 20% of adults and 14% of elderly patients refuse
vaccination because they dislike injections or needles, considering
other ways of vaccine administration an encouraging option to
implement vaccination against influenza.
15-18
Third, the current manufacturing processes of conventional
influenza vaccines are closely dependent on the production of
large virus stocks from embryonated chicken eggs:
19 problems
with surge capacity, egg-adaptation of viral strains, possible con-
taminations, can lead to vaccine shortage, as occurred in 1973 in
the US or antigenic mismatching in 2004.
20,21
Several strategies have been explored both to enhance immune
response after influenza immunization, to improve vaccine accept-
ability and to overcome egg-dependency for vaccine produc-
tion. Innovative approaches include the use of vaccines with an
increased dosage, multiple dose vaccinations, nasal-spray live
attenuated influenza vaccines, vaccines based on conserved anti-
gens, adjuvanted vaccines, alternative cell-based substrates for
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antigen production (mammalian cells or plants), new vaccine
formulations (naked DNA immunization, viral vector based
vaccines), alternative ways of administration, i.e., oral, intranasal,
transcutaneous, intradermic, combined intradermic and intra-
muscular routes. However, most of these new approaches are still
far from commercialization due to safety and immunogenicity
issues, especially in children.
The recent availability of new delivery devices and the percep-
tion of advantages in terms of immunogenicity, safety, reduction
of antigen content and acceptability make intradermal admin-
istration of influenza vaccine a promising alternative to con-
ventional intramuscular route. Although different new tools for
intradermal vaccination have shown promising results in pre-
clinical and clinical trials, only the micro injection system
Soluvia
TM (Becton-Dickinson) has received marketing authoriza-
tion in the European Union and other Countries for the intra-
dermal administration of a trivalent inactivated influenza vaccine,
due to its safety, acceptability, ease of use, and reliability.
22,23
To meet the needs to improve (1) the acceptability of vaccina-
tion in young adults, by administering a low dose of antigen,
and (2) the immunogenicity in the elderly, two intradermal
vaccine formulations have been marketed: Intanza
TM 9 mg and
Fluzone
TM Intradermal, approved for adults 18 through 59 y
in Europe and 18 through 64 y in the USA, respectively, and
Intanza
TM 15 mg approved for elderly in Europe and Canada.
With regards to people , 18 y, one recent study evaluated the
intradermal administration of TIV using Soluvia
TM microinjec-
tion system in children aged 3 or more years, showing the greater
immunogenicity of ID administration and the possibility of dose-
sparing in comparison with conventional TIV.
24
This review examines immunogenicity and acceptability,
tolerability and safety data from clinical trials in healthy volunteers
and at-risk populations, during which influenza vaccines were
administered intradermally, with particular attention to studies
using the innovative injection system Soluvia
TM, currently the
only intradermal device licensed for influenza vaccines.
Immune Mechanisms Elicited After
Intradermal Vaccination
Skin is an efficient and attractive site for vaccination due to its
unique immunological and micro-vascular properties and the
extreme richness in specific resident and recruited antigen-
presenting cells, capable of eliciting both innate and adaptive
immune responses. In particular, the principal immune target of
intradermal vaccination is the dermal population of specialized
dendritic cells, expressing high levels of class II MHC and CD1
molecules, such as Langerhans cells and macrophages infiltrating
dermis tissue after recruitment from circulating blood. These
specialized dendritic cells are extremely efficient in antigen pre-
sentation.
25-27 Immature resident dendritic cells capture and
process the antigens released in the dermis, re-express part of
them as peptide-MHC complexes on the surface, then undergo
functional maturation, acquiring immune stimulatory ability, and
migrate to the paracortical area of the regional draining lymph
nodes, where the peptide-MHC complexes are specifically
recognized by CD8
+ and CD4
+ T cells.
28,29 This mechanism is
activated and promoted by several signaling pathways, including
increased expression of MHC antigens, co-stimulatory molecules
and pro-inflammatory cytokines such as IL-1 β, IL-6, IL-12 and
TNFa.
30 Intradermal antigen delivery also increases the recruit-
ment of dendritic cell precursors from the blood stream to the
dermis and facilitates the lymphatic drainage of free antigen and
the subsequent capture by lymph node-resident dendritic cells
and/or the direct activation of specific B-cell precursors through
interaction with the B-cell receptor (BCR).
28,31,32 The elicited
lymphocyte T CD8
+ population clonally expand and diffuse to
the blood stream, acquiring skin-specific homing antigens (CLA
and CCR4) and becoming effector and memory T cells, while
CD4
+ T cells promote the differentiation of B cells into antibody-
producing plasma cells.
29 Compared with intramuscular vaccina-
tion that activates T-cell response through transient antigen-
presenting cells or free antigen migration to the regional draining
lymph nodes, due to the lack of resident antigen-presenting cells
in muscles, the intradermal route offers a potentially greater
immunogenicity, justified by the direct delivery of antigen to the
skin immune system: results obtained with BCG, rabies, smallpox
and hepatitis B vaccines confirmed this theory.
33-36
New Devices for Intradermal Vaccine Administration
and Overview of the Market
After the introduction of the intradermal injection technique
by Mantoux in 1908
37 and the experience with intradermally
administered typhoid fever vaccine reported by Tuft in 1931,
38
the intradermal route of vaccine delivery has been extensively
studied in order to evaluate immunogenicity, safety and
tolerability of different commercially available vaccines licensed
for intramuscular way but administered intradermally. These
experiences included vaccination against measles,
39,40 cholera,
41
rabies,
42,43 hepatitis B
44-47 and poliomyelitis.
48-51 During the last
century several clinical trials have been performed to evaluate the
safety, tolerability and immunogenicity of intradermal adminis-
tered influenza vaccines, but the absence of a consistent clinical
design and standardized investigational method have not allowed
efficient and significant comparisons and meta-analyses.
52-63
Moreover, the lack of an appropriate, reproducible, easy-to-use
and safe technique has limited the use of intradermal immuniza-
tion, mainly because the Mantoux technique requires specific
skills, special training and experience and the use of conventional
needles do not ensure a precise quantity of antigens and the
appropriate depth of the puncture. To overcome these problems,
in recent years new devices for intradermal vaccination have
been developed and extensively tested. These new delivery
systems provide benefits in terms of ease of use, consistency of
administered volume, accuracy of injection depth and safety of
vaccination, reducing the risk of accidental puncture of health
workers and preventing syringe reuse. Regarding intradermal
influenza vaccination, the most clinically investigated medical
devices are the MicronJet
TM microneedle device (Nanopass)
and the intradermal microinjection system (Soluvia
TM). The first
device consists of an array of four silicon microneedles, each
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0.45 mm in length, which is fixed to an adaptor that could be
mounted on a standard syringe.
64 The second system is a platform
employing a pre-filled, ready to use syringe, the volume of which
ranges from 100 to 200 ml, and a tiny hollow mini needle
approximately 1.5mm in length, able to ensure proper vaccine
delivery in the dermis.
22,23 Due to the very small size of both
devices, vaccine delivery is nearly imperceptible for the patient
and, unlike deep intramuscular injection, the potential risk of
injury to nerves and blood vessels is close to zero, offering a
further advantage in terms of reduction in cross-contamination
risk.
65,66 Other microneedle-based influenza vaccines have been
recently evaluated in a number of preclinical studies, showing
promising results in terms of immunogenicity and dose-sparing
effects.
67-72 Currently, only the micro injection system Soluvia
TM
has received marketing authorization in the European Union, the
USA and other Countries for the intradermal administration of
influenza vaccine.
The first licensed intradermal trivalent inactivated split-virion
influenza vaccines administered using BD’s Soluvia
TM device
are Intanza
TM 9mg and Intanza
TM 15mg (also known in some
countries as IDflu
TM 9mg and IDflu
TM 15mg, sanofi pasteur),
respectively approved for human use in adults aged ,60 y and in
elderly aged .60 y, licensed in the European Union in February
2009 and in Canada in September 2010. On May 10th 2011, the
US. Food and Drug Administration approved the company’s
supplemental biologics license application (sBLA) for licensure of
Fluzone
TM Intradermal (influenza virus vaccine, sanofi pasteur), a
vaccine identical to Intanza
TM 9 mg for antigen content, way of
administration and injection system, indicated for active
immunization of adults aging between 18–64 y.
Immunogenicity
In the present review, immunogenicity results are reported
according to EMA/CHMP criteria, as: mean-fold increase or
geometric mean titer ratio (MFI or GMTR; ratio of post- to pre-
vaccination titer), seroconversion rate (percentage of subjects
with a four-fold increase in HI antibody titer, providing a
minimal post-vaccination titer of 1:40) and seroprotection rate
(the percentage of subjects achieving an HI titer $40). To meet
the CHMP requirements for immunogenicity, at least one of
following criteria must be met for all the three virus strains
included in the vaccine composition
73,74: for adults, the
seroprotection rate must exceed 70% of immunized subjects,
the seroconversion rate 40% and the mean fold increase 2.5; the
respective limits for the elderly are 60%, 30% and 2.0.
Children. Different studies evaluated immunogenicity of
intradermal influenza vaccination in children and infants, but
TIV were always administered using the Mantoux technique and
no firm statements can be made on the basis of obtained data, due
to discrepant immunogenicity results and well-known limitations
of the administration method.
75-78 On August 2011, the results of
a Phase III clinical trial of two different intradermal doses of a
split-virion TIV administered by Soluvia
TM microinjection
system, involving 112 previously primed healthy children aged
$ 3 y, were disseminated. Collected data suggested that the 15 mg
intradermal formulation induced a similar or a significant better
immune response against type A and B strains, respectively,
compared with an intramuscular virosome-adjuvanted influenza
vaccine. Moreover, the 9 mg intradermal formulation showed
similar seroconversion and seroprotection rates and GMT
compared with those obtained with the highest dose of the same
vaccine and with the intramuscular virosome-adjuvanted vaccine
for A/H1N1 and A/H3N2 strains, while for the B strain GMT
was higher than that obtained with virosome-adjuvanted vaccine
and lower than that induced by the highest dose.
24
Healthy volunteers younger than 64 y. We identified four
clinical trials that evaluated the intradermal delivery of influenza
vaccine using the microinjection system Soluvia
TM in healthy
volunteers younger than 64 y, all performed in the past 10 y
79-82;
another study used a tuberculin syringe fitted with a plastic disc to
limit skin penetration and ensure intradermal administration of
the vaccine, thus identifying a forerunner of the Soluvia
TM
device.
83 This last study was performed by Belshe et al. during the
2001–02 season and can be considered the first clinical trial to
evaluate an innovative technique for intradermal vaccination. In
this study, an intradermal injection of a reduced dose of a trivalent
inactivated influenza vaccine (6mg for each strain) resulted in
similarly vigorous antibody responses in the 18–60y group,
compared with an intramuscular injection of a full-dose vaccine
(15mg for each strain): all subjects were seroprotected after
vaccination for the three strains in the vaccine, although a slightly
lower fold increase to the strain B antigens and a lower
seroconversion rate were observed in the intradermal recipients,
probably due to higher pre-vaccination titers in this group.
83 The
ability of a 6mg intradermal vaccine formulation to show similarly
immunogenicity profiles, as compared with an intramuscular
injection of full-dose influenza vaccine among healthy volunteers
younger than 64 y, was not confirmed by all Authors. In a three-
year randomized controlled trial by Beran et al., a 3mg and a 6mg
intradermal formulation of a trivalent inactivated influenza
vaccine induced immune responses inferior to those elicited
by a 15mg intramuscular vaccine and failed to reach CHMP
criteria for B strain, not confirming the results obtained by
Belshe et al.
80 In a large multicenter study, Frenck and colleagues
have recently compared the performance of a 6mg and a
9mg intradermal formulation with a standard full-dose intramus-
cular influenza vaccine, demonstrating the non-inferiority of
the two intradermal vaccines as regards to post-vaccination
Geometric Mean Titers (GMTs) for all the three strains, except
for the subgroup of subjects aged between 50–64y, in which
the 6mg dose given intradermally induced lower GMTs com-
pared with standard intramuscularly TIV for the A/H1N1 and
B strains.
82
Four studies, performed by Beran et al., Leroux-Roels et al.,
Arnou et al. and Frenck et al., demonstrated the ability of the
intradermal vaccine, containing 9mg of HA for each strain, to
elicit equal and sometimes better antibody responses than an
intramuscular TIV influenza vaccine. In these published studies,
including a population of almost 3,000 adults aged ,65 y
receiving at least one dose of intradermal vaccines containing 9mg
HA per strain administered using BD’s Soluvia
TM micro injection
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system—intradermal vaccine fulfilled all three the CHMP criteria
for all the three vaccine strains with few exceptions.
79-82 In the
study performed by Leroux-Roels et al. subjects vaccinated with
intradermal vaccine showed superior humoral immune responses
against both A strain (H1N1, H3N2) compared with the intra-
muscular group, while Beran and colleagues observed GMTRs
, 2.5 and seroconversion rates , 40% against A(H1N1) and B
strains in both intradermal and intramuscular groups, showing a
very similar immunogenicity profile of the two formulations.
79,80
As observed by many Authors for intramuscular vaccines,
Frenck et al. demonstrated an inverse correlation between
immune response and age also in intradermal vaccine recipients:
the percentage of younger adults (18–49 y of age) who achieved a
post-vaccination HAI $40 and an higher GMT responses were
significantly greater than in subjects of 50–64 y of age for each
vaccine strain (p # 0.01).
82 In Table1 the principal character-
istics of the cited studies and the immunogenicity results in
healthy volunteers younger than 64 y are reported.
Elderly and immunocompromised patients. Four studies
evaluated the immunogenicity profile provided by an intradermal
influenza vaccine administered using BD’s Soluvia
TM device in
elderly subjects aged .60 y and results obtained by using 15 mg
per strain intradermal formulations showed a clear superiority
compared with the intramuscular split vaccine and a non-
inferiority respect to the intramuscular MF59-adiuvanted vac-
cine.
83-86 In the already-cited study by Belshe et al., intradermal
vaccination with 6 mg HA per strain elicited a vigorous immune
response in subjects .60 y, comparable to that provided by the
conventional 15 mg intramuscular vaccine, with the only
exception for H3N2 antigen, for which a significantly higher
response was observed in the intramuscular group.
83 Holland and
colleagues assessed the performance rates of two intradermal
formulations, containing 15 and 21 mg HA per strain, in subjects
.60 y, 40% of which presenting at least one medical condition
that placed the subject at risk for influenza-related complications:
both intradermally delivered vaccines were significantly superior
to intramuscular control vaccine for each strain in terms of post-
vaccination GMT, GMTR, seroprotection and seroconversion
rates, except for the rate of seroprotection against H1N1 antigens
in the 15 mg intradermal group, which did not reach signifi-
cance.
84 In adults aged $60 y, most of whom (66%) with risk
conditions for complicated influenza, one dose of a 15 mg
influenza vaccine given intradermally showed superior antibody
responses against each vaccine antigen compared with the intra-
muscular control vaccine also in a 3-y, phase III, multicenter
study performed by Arnou et al. Moreover, intradermal vaccine
Table1. Immunogenicity profile of intradermal vaccines in healthy volunteers ,65 y
Authors
No. of subjects
(intradermal)
Age
range
Study
year
Intradermal
antigen dose
Immunogenicity (CHMP criteria)
Seroprotection rate (%) Seroconversion rate (%) GMT ratio
H1N1 H3N2 B H1N1 H3N2 B H1N1 H3N2 B
Belshe 123 (60) 18–60 y 2001–02 6 mg 100.0 100.0 100.0 31.7 35.0 25.0 4.0 4.0 2.4
Leroux-Roels 766 (382) 18–57 y 2005–06 9 mg 92.4 99.7 90.6 74.3 85.1 76.4 16.2 28.2 12.1
Beran 762 (382) 18–57 y 2003–04 3 mg 72.7 88.5 28.5 53.1 35.4 21.0 7.32 3.48 2.38
761 (381) 18–57 y 2003–04 6 mg 71.3 88.2 32.9 55.1 43.0 27.3 8.38 4.19 2.73
1086 (541) 19–58 y 2004–05 9 mg 90.0 97.2 73.0 43.0 53.1 63.4 4.3 4.4 7.8
826 (417) 20–59 y 2005–06 9 mg 90.7 100.0 83.3 14.8 60.2 24.1 2.0 4.6 2.3
Arnou 1744 (1308) 18–60 y 2006 9 mg 87.2 93.5 72.9 57.5 66.5 56.7 9.17 11.5 6.39
Frenck Jr 1591 (399) 18–64 y 2005–06 6 mg 76.5 99.7 75.0 - - - 3.62 3.59 4.78
1591 (394) 18–64 y 2005–06 9 mg 81.0 99.5 76.2 - - - 3.92 4.03 5.59
Table2. Immunogenicity profile of intradermal vaccines in elderly
Authors No. of subjects
(intradermal)
Age
range
Study
year
Intradermal
antigen dose
Immunogenicity (CHMP criteria)
Seroprotection rate (%) Seroconversion rate (%) GMT ratio
H1N1 H3N2 B H1N1 H3N2 B H1N1 H3N2 B
Belshe 102 (56) .60 y 2001–02 6 mg 100.0 92.9 100.0 17.9 16.1 17.9 1.9 2.1 2.0
Holland 1101 (366) .60 y 2006 15 mg .70 .90 .80 .40 .40 .40 .3 .4 .3
1101 (369) .60 y 2006 21 mg .80 .90 .80 .40 .40 .40 .4 .5 .4
Arnou 3685 (2604) .60 y 2006 15 mg .70 .90 .50 .30 .60 .30 .3 .8 .3
407 (133) .60 y 2007 15 mg 95.5 98.5 55.6 74.2 36.6 14.3 9.64 2.92 1.77
468 (121) .60 y 2008 15 mg 81.8 92.6 70.2 37.2 73.6 47.1 2.88 8.45 3.76
Van Damme 790 (395) .65 y 2007 15 mg 81.3 .90 .50 .60 .40 .20 .8 .4 .2
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met not only the European CHMP requirements defined for
adults aged .60 y for almost all the vaccine strain, but also the
more rigorous criteria established for younger adults for H1N1
and H3N2 seroprotection rates, H3N2 seroconversion rate and
GMTRs for all strains.
85 Van Damme et al. demonstrated the
non-inferiority of a 15 mg intradermal vaccine compared
with a licensed MF59
TM-adjuvanted vaccine in elderly subjects
aged $65 y: in the immunogenicity assessment by the HI and the
Single Radial Hemolysis (SRH) methods, the results for all three
strains satisfied all the CHMP immunogenicity criteria, with the
exception of seroprotection and seroconversion rates for strain B
antigens by using the HI assay.
86 The global population included
in the studies conducted on adults aged $60 y using an
intradermal vaccine containing 15mg HA per strain and delivered
by micro injection system BD’s Soluvia
TM was about 3,400
subjects. In Table2, the principal characteristics of the cited
studies and the immunogenicity results in elderly subjects aged
.60 y are reported.
Only one study performed by Morelon et al. assessed the
immunogenicity of a 15mg intradermally administered influenza
vaccine in immunocompromised patients, namely a renal
transplant population previously identified as non-responder to
a plain intramuscular vaccine. In this randomized, open-label,
phase II descriptive study, enrolling 62 subjects, intradermal
formulation elicited HI antibody responses higher than conven-
tionally administered TIV, and CHMP criteria were met for
H1N1 and H3N2 GMTRs and for H1N1 and B seroprotection
rates in the intradermal group, while none of the CHMP
requirements were met in the control group.
87
Safety, Tolerability and Acceptability
In terms of safety and reactogenicity, CHMP guidelines state that
within 3d of vaccination the following reactions need to be
assessed: injection site duration .5cm observed for .3d,
injection site ecchymosis, body temperature of .38.0°C for
$24h, malaise, and shivering. It is noteworthy that CHMP
reactions were specifically designed to determine the reactogeni-
city of intramuscular vaccine and may not be fully appropriate to
assess the tolerability profile of intradermal vaccination.
73,74
BD’s Soluvia
TM microinjection system. The intradermal
microinjection system BD’s Soluvia
TM has been evaluated for
performance and safety in two sponsored pivotal clinical trials
(BDPS 05–01 and BDPS 05–02), conducted on 645 adults
(age range 18–80y) receiving saline solution without antigen.
Assessments of skin reactivity at the injection site, local and
systemic adverse events, the intensity of perceived pain during
needle insertion, and fluid infiltration were performed. The
observed local adverse events associated with the new injection
technique did not significantly differ from reactions in subjects
injected with standard Mantoux method. They spontaneously
reversed within 20–30min without sequel or requirement of any
medical intervention and no serious adverse events were reported.
Importantly, pain after the micro injection procedure was signifi-
cantly lower than with standard Mantoux injection technique: it
was usually reported as a faint burning perception and its intensity
was a third compared with that observed in subjects injected using
the standard Mantoux technique (p , 0.0001) according to
the visual analog scale (VAS). Thus, BD’s Micro Injection System
Soluvia
TM met the safety criteria required to successfully
administer vaccines in a clinical setting representing a viable
alternative to imtramuscular immunization.
22
Children. Esposito et al. reported also safety and reactogenicity
assessments of the two different formulations of intradermal
vaccine administered by Soluvia
TM microinjection system in a
population of previously primed healthy children aged $3y.
Local adverse events, in particular swelling/induration and pain,
were significantly more frequent among the children receiving
both 9 and 15mg intradermal formulation than among those
receiving an intramuscular virosome-adjuvanted influenza vaccine,
but they lasted no more than two days and did not require any
medical intervention. The incidence of systemic reactions was low
and comparable between the vaccine groups and no serious
adverse events were reported. No differences between the two
intradermal formulations were observed in terms of recorded
adverse events.
24
Healthy volunteers younger than 64 y. In all published studies
evaluating safety profile of influenza vaccines given intradermally
using BD’s micro injection system Soluvia
TM in healthy adults
younger than 64 y, reactogenicity of the intradermal formulations
was comparable to that of control intramuscular vaccines in terms
of both CHMP reactions, solicited systemic reactions and
spontaneously reported adverse events.
79-83 In fact, in all studies,
no significant differences in the incidence of reactions included in
the CHMP guideline between intradermally BD’s Soluvia and
intramuscularly administered influenza vaccines were observed.
Principal characteristics of the cited studies and percentage of
subjects with CHMP reactions after intradermal influenza
vaccination in this age group are reported in Table3. Leroux-
Roels et al. and Arnou et al. reported a higher incidence of malaise
and injection site ecchymosis in intradermal recipients than other
studies, but a similar proportion of participants in the respective
intramuscular control groups also experienced these reactions.
79,81
Among solicited systemic reactions not included in the CHMP
criteria, headache, myalgia, and fever of any temperature occurred
at similar rates in intradermal and intramuscular groups, with the
exception of myalgia which was more frequent after intramuscular
vaccination, according to Leroux-Roels et al. and Arnou et al.
79,81
As regards solicited injection site reactions within 7 d of vaccina-
tion, significant local inflammatory signs occurred mostly in those
receiving intradermal vaccinations as compared with intramus-
cular injection groups. Injection site erythema, swelling, mild
induration, pruritus (itching) and redness were the more
frequently reported local reactions, affecting 29–88% of intra-
dermal recipients vs. 6–26% of intramuscular vaccinated subjects.
However, these local reactions were not associated with an
increased incidence of injection site pain: notably, a trend for
fewer reports of pain after intradermal vaccination has been
reported by different Authors.
81-83 Inflammatory local symptoms
were mainly of mild or moderate severity, lasted on average two
or three days and all resolved spontaneously without sequelae
and/or medical interventions. Interestingly, Beran and colleagues
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demonstrated that prior intradermal vaccination did not adversely
affect the safety profile of subsequent intramuscular or intrader-
mal injections, suggesting that influenza intradermal vaccination
can be repeated annually without increasing reactogenicity.
80
Both in terms of unsolicited adverse reactions occurring within
21 d after vaccination and serious adverse events reported up to six
months after vaccination, intradermal and intramuscular vaccine
groups were comparable and no safety concerns were raised when
using intradermal influenza vaccines delivered by BD’s Soluvia
TM
device, from available data in healthy adults ,64y.
79-83
Elderly and immunocompromised patients. The analysis of
safety and tolerability data from the three available studies
reporting CHMP local reactions performed in older adults aged
.60 y highlighted a comparable incidence in intradermal and
intramuscular vaccine groups.
84-86 Holland et al. observed a higher
incidence of injection site ecchymosis in patients receiving a 15 mg
dose of intradermal vaccine than that observed in the intramus-
cular group.
84 With regard to solicited reactions occurring within
7d after vaccination, the incidence of systemic reactions, mostly
of mild intensity and lasting #3 d, was comparable between the
vaccine groups, while intradermal recipients reported higher rates
of injection site reactions, namely erythema (63–79% of patients),
induration (33–67%), swelling (34–62%) and pruritus (28–
30%).
83-86 In contrast, injection site pain occurred at similar rates
in both intradermal and intramuscular groups.
83,84,86 More than
95% of the solicited injection site reactions were transient, lasted
3 d or less and were considered of mild severity.
84-86 Unsolicited
adverse events reported within 21 d after vaccination occurred at a
comparable frequency in both vaccine groups; Holland and
colleagues reported a slightly higher incidence of injection site
warmth in patients receiving 15 or 21 mg intradermal influenza
vaccine.
84 Similar percentages of subjects in both intradermal
and intramuscular vaccine groups reported at least one serious
adverse event, most of which were unrelated to vaccination, and
revealed no safety issue.
83-86 Principal characteristics of the cited
studies and percentage of subjects with CHMP reactions after
intradermal influenza vaccination in adults .60 y are reported
in Table 4.
Morelon et al. reported safety evaluations of an intradermal
vaccine containing 15mg HA per strain in a population of renal
transplant recipients on chronic immunosuppressive therapy. As
described for healthy adults and elderly, injection site reactions
(erythema, swelling, induration and pruritus) were more frequent
in the intradermal vaccine group than in the intramuscular
control group; incidence of injection pain was comparable in the
two study groups; no unsolicited adverse events and no clinical
signs of transplant rejection were reported.
87
Intradermal vaccine acceptability. Two recent studies esti-
mated perception, acceptance and willingness to get vaccinated
with an intradermal influenza vaccine administered by BD’s
micro injection system, in European adults and elderly enrolled
in two phase III clinical trials and recruited from a consumer
panel, respectively.
88,89 Reygrobellet et al. administered a validated
questionnaire to 1,679 adults ,60y and 2,262 elderly .60y
respectively receiving one dose of a 9mgo r1 5 mg intradermal
influenza vaccine, enrolled in five European countries during two
large comparative clinical trials. Answers about anxiety before and
after vaccination, bother from pain during injection, acceptability
Table3. Reactogenicity profile in healthy volunteers ,65 y: Difference in incidence of adverse events in subjects immunized with intradermal and
intramuscular vaccines, respectively
Authors No. of subjects
(intradermal)
Age
range
Study
year
Intradermal
antigen dose
Reactogenicity (CHMP criteria)
(difference intradermal-intramuscular: % of subjects)
Injection site
induration
Injection site
ecchymosis
Fever
. 38.0°
Malaise Shivering
Leroux-Roels 978 (588) 18–57 y 2005–06 9 mg +0.2 -0.8 +0.7 -2.8 -1.4
Beran 766 (384) 18–57 y 2003–04 3 mg -0.3 -1.3 -0.6 -1.9 +1.3
765 (383) 18–57 y 2003–04 6 mg -0.3 -1.5 -0.3 -0.6 +1.3
1091 (544) 19–58 y 2004–05 9 mg +0.9 -0.2 +0.6 -1.1 -0.5
828 (418) 20–59 y 2005–06 9 mg 0 -0.3 +1.9 -1.1 +0.8
Arnou 1744 (1308) 18–60 y 2006 9 mg +0.1 -2.5 +1.4 -2.4 +1.0
Table4. Reactogenicity profile in elderly: Difference in incidence of adverse events in subjects immunized with intradermal and intramuscular vaccines,
respectively
Authors No. of subjects
(intradermal)
Age
range
Study
year
Intradermal
antigen dose
Reactogenicity (CHMP criteria)
(difference intradermal-intramuscular: % of subjects)
Injection site
induration
Injection site
ecchymosis
Fever
. 38.0°
Malaise Shivering
Holland 1101 (366) .60 y 2006 15 mg 0 +3.6 -0.5 +2.6 0
1101 (369) .60 y 2006 21 mg 0 -1.1 0 +0.3 +1.3
Arnou 3695 (2606) .60 y 2006 15 mg +0.1 -0.2 -0.3 +0.8 -0.7
Van Damme 790 (395) .65 y 2007 15 mg 0 +0.3 -1.5 -0.2 +0.2
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of local reactions, satisfaction with the injection system and
willingness to be re-vaccinated were recorded and compared
with the control intramuscular population, revealing no marked
differences between vaccine groups. Levels of injection site
reactions acceptability, satisfaction and willingness to be re-
vaccinated were high in both intradermal and intramuscular
groups: more than 96% of participants rated local reactions after
vaccination as either “totally acceptable” or “very acceptable,”
more than 92% were “very satisfied” or “satisfied,” more than
81% answered “yes, definitely” or “yes, probably” about willing-
ness to be re-vaccinated. The perception of the injection site
reactions, although markedly more frequent in intradermal
vaccine recipients, was not a cause for concern and did not
negatively affect acceptability, satisfaction and willingness to get
vaccinated the following year.
88 Arnou et al. investigated whether
the availability of Intanza
TM 9 mg and Intanza
TM 15 mg (sanofi
pasteur) might influence physicians and general public likelihood
of recommending or seeking seasonal influenza vaccination.
Although participants based their responses only on investiga-
tional information about intradermal vaccine, rather than experi-
ence of using or receiving it, making these surveys theoretical,
results indicated that physicians would prefer Intanza
TM to
conventional intramuscular vaccination, perceiving its benefits in
terms of shorter needles and immunogenicity. Moreover, the
general public would be encouraged to get vaccinated, perceiving
that intradermal route of administration reduces apprehension
and fear associated with annual influenza vaccination.
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Conclusions
Data from clinical trials performed on children, adults aged
,60y and in elderly people and post-marketing surveillance
demonstrated that actually, licensed intradermal vaccines
showed an excellent acceptability, safety and tolerability profile.
Immunogenicity of 9mg and 15 mg formulations was compar-
able and superior to conventional intramuscular vaccines, res-
pectively. Higher immunogenicity offered by Intanza
TM 15 mg
was essentially demonstrated in elderly adults, 21 d after
immunization and against homologous egg-grown vaccine
strains. Several unknown aspects deserve more in-depth
studies: immune response and safety and tolerability profile in
younger unprimed children, antibody persistence 3–5 mo after
vaccination, cross-reactive immune response against drifted
strains or heterologous viruses, cellular immune response,
priming-effect against potentially pandemic deserve further
research to better define the potential of intradermal vaccine.
Data on the higher ability of intradermal vaccine to elicit cross-
reactive antibodies against heterologous circulating viruses than
intramuscular formulation were recently reported by Ansaldi
et al. (The Fourth ESWI Influenza Conference, Malta, September
2011).
Moreover, clinical trials are needed to evaluate the advantages
offered by use of Intanza
TM 15 mg, currently only approved for
the elderly population, or Intanza
TM 9 mg in low responders aged
,60 y, such as immunocompromised subjects or patients with
chronic diseases. Furthermore, although greater immunogenicity
induced by Intanza
TM 15 mg has been observed in a number of
studies, it is not yet clear how this translates into protection
against influenza and influenza-related complications and morta-
lity. Comparisons between the effectiveness of the intradermal
formulation and that of plain intramuscular vaccine may provide
evidence on the advantages offered by “implemented” vaccine in
terms of clinical effects.
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